The Power of Prevention: The Untapped Potential of Adult Immunisation Programmes

By Staff Writer

January 1, 2024

The Unseen Value of Adult Immunisation

Adult immunisation programmes are often overlooked. But these are critical to addressing key health and societal challenges. A detailed review by the  Office of Health Economics (OHE) of these programmes has recently been conducted. Focusing on diseases such as seasonal influenza, pneumococcal disease, herpes zoster, and respiratory syncytial virus, reveals their crucial role in global health. The benefits of these programmes extend beyond health, impacting social care systems and aligning with global agendas such as the UN Sustainable Development Goals (SDGs) and the WHO Immunisation Agenda 2030 (IA2030). However, the full value of such programmes is often underestimated due to underrepresentation in academic literature, leading to suboptimal investment decisions.

The Rising Burden of Infectious Diseases and Ageing Populations

The world is witnessing significant demographic shifts, with ageing populations becoming a dominant trend. Infectious diseases like shingles and pneumococcal disease pose severe threats to older adults, leading to substantial hospitalisation burdens. Alongside this, the ‘tripledemic’ of COVID-19, seasonal influenza, and RSV, coupled with rising rates of chronic diseases among younger age groups, is exerting immense pressure on healthcare systems. This necessitates a shift from treatment to prevention, with vaccination standing as a fundamental preventive measure.

The Economic and Health Benefits of Adult Immunisation

Adult immunisation programmes are not just health measures, but also economically beneficial strategies. They are cost-effective and can result in net cost savings for healthcare systems. Recent studies in Australia and Germany underline that these programmes offer financial gains by averting hospital inpatient and emergency care. Expanding adult immunisation programmes and coverage can lead to substantial productivity gains and economic benefits for society. Moreover, these programmes can contribute to health and economic equity within countries, benefiting vulnerable and underserved communities.

The Urgent Need for Further Research and Adoption of a Preventive Mindset

Despite the clear benefits, significant gaps exist in evidence regarding the broader elements of the value of immunisation programmes. This calls for urgent research to prioritise and enhance adult immunisation programmes for the benefit of society and public health. It is vital for policy- and decision-makers to adopt a prevention-first mindset and implement robust adult immunisation programmes that are proven cost-effective. Expanding the evidence base for the broader value of adult immunisation is a crucial step towards optimising the value of these programmes.

Conclusion: The Power of Prevention

Adult immunisation programmes are powerful tools in the fight against infectious diseases and the burden they place on healthcare systems. They are cost-effective, promote health equity, and align with global health goals. However, their full potential remains untapped, largely due to underrepresentation in academic literature and a lack of awareness among decision-makers. It’s time to shift our focus from treatment to prevention and recognise the immense value that adult immunisation programmes bring to society.

Reference url

Recent Posts

U.S. withdraws from WHO
     

U.S. Withdraws from WHO: Impact on Global Health Security and Relations

🚨 *What does the U.S. withdrawing from the WHO mean for global health?*
President Trump’s executive order to begin the withdrawal process raises serious concerns about the future of global health security. From financial disparities to a shift in international partnerships, the implications could reshape our collective ability to combat pandemics and health crises.

Dive into our article to understand the potential impacts on health outcomes and the quest for new alliances.

#SyenzaNews #globalhealth #healthcarepolicy

semaglutide NAION risk
    

Semaglutide NAION Risk: EMA Review Initiated Amid Conflicting Evidence

🔍 Is semaglutide linked to vision loss?

The European Medicines Agency’s PRAC is currently reviewing the potential risk of non-arteritic anterior ischemic optic neuropathy (NAION) associated with semaglutide-containing medicines, including popular treatments like Ozempic and Wegovy. With recent studies yielding conflicting evidence, this review is crucial for patient safety and the future of these therapies.

Read the full article to understand the implications and what this could mean for healthcare providers and patients alike!

#SyenzaNews #Pharmaceuticals #HealthcarePolicy

cervical cancer screening
        

Cost-Effective Cervical Cancer Screening Strategies for Women with HIV in KwaZulu-Natal

💡 *Are single-visit cervical cancer screenings the key to better health outcomes in high HIV prevalence areas?*
A recent study from KwaZulu-Natal, South Africa reveals that repeat single-visit cervical cancer screening using HPV DNA testing is not only the most effective but also the most cost-effective approach for women living with HIV. This aligns with WHO recommendations for comprehensive cervical cancer elimination strategies.

Explore the insights and implications of this vital research that could transform cervical cancer prevention in resource-limited settings.

#SyenzaNews #HealthEconomics #oncology #GlobalHealth

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.